DSM\nVenturing has made an equity investment in skin microbiome company S-Biomedic.\nThis investment completes S-Biomedic\u2019s latest Series A financing round. S-Biomedic\nis a Belgium based Life Sciences company pioneering a new approach to cosmetic\nand therapeutic potential of the skin microbiome.<\/p>\n\n\n\n
This\ninvestment underlines DSM\u2019s interest in the skin microbiome, an area it has\nidentified as having significant growth potential. DSM already holds a strong\nposition in gut microbiome research and solutions with its Culturelle\u00ae product\nrange.<\/p>\n\n\n\n
\u201cWith its\nlong-established expertise in skin biology and in-depth knowledge in the field\nof epidermal science DSM is well placed to extend its research and innovation\nfocus on the skin microbiome. We have already made encouraging discoveries\nabout how skin actives in our existing product portfolio work on the skin and\nscalp microbiome. Through this investment, we hope to foster further innovation\nin the field\u201d commented Rishabh Pande, Vice President Marketing &\nInnovation Personal Care & Aroma at DSM.<\/p>\n\n\n\n
DSM Venturing has invested in more than 50 emerging innovative companies since its inception in 2001 and its current portfolio covers various industries. \u201cDSM welcomes open innovation, as our history of investing in start-ups and taking on the role of incubator shows,\u201d comments Rob Beudeker, Investment Director at DSM Venturing.<\/p>\n\n\n\n